AbbVie Asks Fed. Circ. To Revive Antibody Patent Suit

Law360, Los Angeles (August 22, 2013, 5:57 PM ET) -- AbbVie Deutschland GmbH & Co. on Monday asked the Federal Circuit to reverse a jury’s decision invalidating as obvious a pair of patents covering genetically engineered human antibodies to interleukin 12, a protein whose overproduction is associated with psoriasis and rheumatoid arthritis.

The request comes after U.S. District Judge F. Dennis Saylor IV denied AbbVie’s renewed motion for judgment as a matter of law in March, affirming the jury’s verdict and holding that there was a reasonable expectation that the use of transgenic mice would produce...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required